Growth patterns of pituitary adenomas and histopathological correlates

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 4, 2014, Pages 1330-1338

  Monsalves, Eric ^a,b   Larjani, Soroush ^b   Godoy, Bruno Loyola ^b   Juraschka, Kyle ^b   Carvalho, Felipe ^b   Kucharczyk, Walter ^c   Kulkarni, Abhaya ^d   Mete, Ozgur ^a,c   Gentili, Fred ^b   Ezzat, Shereen ^a,c   Zadeh, Gelareh ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; CELL PROLIFERATION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PITUITARY NEOPLASMS; PREOPERATIVE PERIOD; PROGNOSIS; TUMOR BURDEN;

EID: 84897039033     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3054     Document Type: Article

References (42)

1. Asa SL, Ezzat S. The pathogenesis of pituitary tumors. Annu Rev Pathol. 2009;4:97-126.
2. Mete O, Asa SL. Clinicopathological correlations in pituitary adenomas. Brain Pathol. 2012;22(4):443-453.
3. Mete O, Ezzat S, Asa SL. Biomarkers of aggressive pituitary adenomas. J Mol Endocrinol. 2012;49(2):R69-R78.
4. Benveniste RJ, King WA, Walsh J, Lee JS, Delman BN, Post KD. Repeated transsphenoidal surgery to treat recurrent or residual pituitary adenoma. J Neurosurg. 2005;102(6):1004-1012.
5. Alahmadi H, Dehdashti AR, Gentili F. Endoscopic endonasal surgery in recurrent and residual pituitary adenomas after microscopic resection. World Neurosurg. 2012;77(3-4):540-547.
6. Zada G, Lin N, Laws ER Jr. Patterns of extrasellar extension in growth hormone-secreting and nonfunctional pituitary macroad-enomas. Neurosurg Focus. 2010;29(4):E4.
7. Lundin P, Nyman R, Burman P, Lundberg PO, Muhr C. MRI of pituitary macroadenomas with reference to hormonal activity. Neu-roradiology. 1992;34(1):43-51.
8. Scheithauer BW, Kovacs KT, Laws ER Jr, Randall RV. Pathology of invasive pituitary tumors with special reference to functional classification. J Neurosurg. 1986;65(6):733-744.
9. Prevedello DM, Jagannathan J, Jane JA Jr, Lopes MB, Laws ER Jr. Relevance of high Ki-67 in pituitary adenomas. Case report and review of the literature. Neurosurg Focus. 2005;19(5):E11.
10. Chacko G, Chacko AG, Kovacs K, et al. The clinical significance of MIB-1 labeling index in pituitary adenomas. Pituitary. 2010;13(4): 337-344.
11. Noh TW, Jeong HJ, Lee MK, Kim TS, Kim SH, Lee EJ. Predicting recurrence ofnonfunctioningpituitaryadenomas. JClinEndocrinol Metab. 2009;94(11):4406-4413.
12. Trouillas J, Roy P, Sturm N, et al. A new prognostic clinicopatho-logical classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol. 2013;126(1):123-135.
13. Shrestha R, Qi L, Bao G, Wang MD. Prospective study of trans-sphenoidal pituitary surgery: is tumor volume a predictor for the residual tumor? Chin Med J (Engl). 2012;125(14):2444-2448.
14. Ringstad GA, Emblem KE, Holland D, Dale AM, Bjornerud A, Hald JK. Assessment of pituitary adenoma volumetric change using lon-gitudinalMR image registration. Neuroradiology. 2012;54(5):435-443.
15. Jain AK, Gupta AK, Pathak A, Bhansali A, Bapuraj JR. Endonasal transsphenoidal pituitary surgery: is tumor volume a key factor in determining outcome? Am J Otolaryngol. 2008;29(1):48-50.
16. Kawamoto H, Uozumi T, Kawamoto K, Arita K, Yano T, Hirohata T. Analysis of the growth rate and cavernous sinus invasion of pituitary adenomas. Acta Neurochir (Wien). 1995;136(1-2):37-43.
17. Ekramullah SM, Saitoh Y, Arita N, Ohnishi T, Hayakawa T. The correlation of Ki-67 staining indices with tumour doubling times in regrowing non-functioning pituitary adenomas. Acta Neuro-chirurg. 1996;138(12):1449-1455.
18. Tanaka Y, Hongo K, Tada T, Sakai K, Kakizawa Y, Kobayashi S. Growth pattern and rate in residual nonfunctioning pituitary adenomas: correlations among tumor volume doubling time, patient age, and MIB-1 index. J Neurosurg. 2003;98(2):359-365.
19. Hsu CY, Guo WY, Chien CP, Ho DM. MIB-1 labeling index correlated with magnetic resonance imaging detected tumor volume doubling time in pituitary adenoma. Eur J Endocrinol. 2010;162(6): 1027-1033.
20. Saeger W, Ludecke B, Ludecke DK. Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas. Exp Clin Endocrinol Diabetes. 2008;116(2):80-85.
21. Honegger J, Prettin C, Feuerhake F, Petrick M, Schulte-Monting J, Reincke M. Expression of Ki-67 antigen in nonfunctioning pituitary adenomas: correlation with growth velocity and invasiveness. J Neurosurg. 2003;99(4):674-679.
22. Yushkevich PA, Piven J, Hazlett HC, et al. User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage. 2006;31(3):1116-1128.
23. Ebinu JO, Lwu S, Monsalves E, et al. y knife radiosurgery for the treatment of cystic cerebral metastases. Int J Radiat Oncol Biol Phys. 2013;85(3):667-671.
24. Knosp E, Steiner E, Kitz K, Matula C. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery. 1993; 33(4):610-617; discussion 617-618.
25. Nakaguchi H, Fujimaki T, Matsuno A, et al. Postoperative residual tumor growth of meningioma can be predicted by MIB-1 immuno-histochemistry. Cancer. 1999;85(10):2249-2254.
26. Christmann AVA. Robust estimation of Cronbach's a. J Multivariate Anal. 2006;97(7):1660-1674.
27. Thapar K, Kovacs K, Scheithauer BW, et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery. 1996;38(1):99-106; discussion 106-107.
28. Wolfsberger S, Wunderer J, Zachenhofer I, et al. Expression of cell proliferation markers in pituitary adenomas-correlation and clinical relevance of MIB-1 and anti-topoisomerase-II a. Acta Neuro-chirurg. 2004;146(8):831-839.
29. Morita K, Takano K, Yasufuku-Takano J, et al. Expression of pituitary tumour-derived, N-terminally truncated isoform of fibroblast growth factor receptor 4 (ptd-FGFR4) correlates with tumour invasiveness but not with G-protein a subunit (gsp) mutation in human GH-secreting pituitary adenomas. Clin Endocrinol (Oxf). 2008;68(3):435-441.
30. QianZR, Sano T, Asa SL, etal. Cytoplasmic expressionoffibroblast growth factor receptor-4 in human pituitary adenomas: relation to tumor type, size, proliferation, and invasiveness. J Clin Endocrinol Metab. 2004;89(4):1904-1911.
31. Zhao D, Tomono Y, Nose T. Expression of P27kip1 and Ki-67 in pituitary adenomas: an investigation of marker of adenoma inva-siveness. Acta Neurochir (Wien). 1999;141(2):187-192.
32. Ezzat S, Zheng L, Winer D, Asa SL. Targeting N-cadherin through fibroblast growth factor receptor-4: distinct pathogenetic and therapeutic implications. Mol Endocrinol. 2006;20(11):2965-2975.
33. Korbonits M, Chahal HS, Kaltsas G, et al. Expression of phosphor-ylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors. J Clin Endocrinol Metab. 2002; 87(6):2635-2643.
34. ChuIM, Hengst L, SlingerlandJM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer. 2008;8(4):253-267.
35. Musat M, Korbonits M, Kola B, et al. Enhanced protein kinase B/Akt signalling in pituitary tumours. Endocr Relat Cancer. 2005; 12(2):423-433.
36. Komatsubara K, Tahara S, Umeoka K, Sanno N, Teramoto A, Os-amura RY. Immunohistochemical analysis of p27 (Kip1) in human pituitary glands and in various types of pituitary adenomas. Endocr Pathol. 2001;12(2):181-188.
37. Hewedi IH, Osman WM, El Mahdy MM. Differential expression of cyclin D1 in human pituitary tumors: relation to MIB-1 and p27/ Kip1 labeling indices. J Egypt Natl Cancer Inst. 2011;23(4):171-179.
38. Losa M, Mortini P, Barzaghi R, et al. Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence. J Neurosurg. 2008;108(3):525-532.
39. Rudnik A, Zawadzki T, Galuszka-Ignasiak B, et al. Endoscopic transsphenoidal treatment in recurrent and residual pituitary adenomas-first experience. Minim Invas Neurosurg. 2006;49(1):10-14.
40. Cappabianca P, Alfieri A, Colao A, et al. Endoscopic endonasal transsphenoidal surgery in recurrent and residual pituitary adenomas: technical note. Minim Invas Neurosurg. 2000;43(1):38-43.
41. Chen Y, Wang CD, Su ZP, et al. Natural history of postoperative nonfunctioning pituitary adenomas: a systematic review and meta-analysis. Neuroendocrinology. 2012;96(4):333-342.
42. Widhalm G, Wolfsberger S, Preusser M, et al. Residual nonfunc-tioning pituitary adenomas: prognostic value of MIB-1 labeling index for tumor progression. J Neurosurg. 2009;111(3):563-571.